Immugenia Inc. is a Canadian, immuno-oncology company developing a novel approach to CAR therapy by engineering hematopoietic stem cells to treat cancer and prevent relapses, potentially for life. Unlike existing CAR-T or CAR-NK therapies, our proprietary specific synthetic promoters’ technology allows for the CAR to be expressed selectively in both T and NK cells from one treatment, in order to leverage their synergistic immune activity, as nature intended, against cancer.
Our specific promoters can also be used in iPSC (induced pluripotent stem cells) ensuring that gene expression only occurs in the fully differentiated cell of interest and thus, not impede on the cell differentiation process. Beyond immune cell applications, Immugenia’s platform can develop synthetic promoters for specific cell type (hepatocytes, cardiac cells, glial cells, etc.) for in vivo gene expression in the targeted cells.
Immugenia is developing its own drug candidates in liquid and solid tumors for an eventual licensing agreement. We are also interested in the co-development of drug candidates with companies interested in the cell & gene therapy either in oncology, rare genetic diseases or regenerative medicines.
Our specific promoters can also be used in iPSC (induced pluripotent stem cells) ensuring that gene expression only occurs in the fully differentiated cell of interest and thus, not impede on the cell differentiation process. Beyond immune cell applications, Immugenia’s platform can develop synthetic promoters for specific cell type (hepatocytes, cardiac cells, glial cells, etc.) for in vivo gene expression in the targeted cells.
Immugenia is developing its own drug candidates in liquid and solid tumors for an eventual licensing agreement. We are also interested in the co-development of drug candidates with companies interested in the cell & gene therapy either in oncology, rare genetic diseases or regenerative medicines.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
